IGF1R and Hyperglycemia: Despite some cases showing exceptional responses, the majority of trials involving IGF-1R inhibitors have failed, due to factors including lack of predictive biomarkers, dose-limiting hyperglycaemia resulting from co-inhibition of INSR, and incomplete understanding of IGF-1R biology [8–10].